Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
NCT01484093 is a phase 1/2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Mantle Cell Lymphoma. The registry lists an enrollment of 96 participants at 5 sites in 1 country. The registry lists a start date of 29 Nov 2011 and a primary completion date of 11 Aug 2023. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01484093 |
| Status | Completed |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
| Enrollment | 96 |
| Registered sites | 5 |
| Countries | 1 |
| Conditions | Mantle Cell Lymphoma |
| Start | 29 Nov 2011 |
| Primary completion | 11 Aug 2023 |
| Study completion | 11 Aug 2023 |
| Last update posted | 16 Aug 2023 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge
- Memorial Sloan Kettering Cancer Center @ Suffolk
Commack
- Memorial Sloan Kettering Cancer Center
New York
- Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre
- Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT01484093
Each answer restates registry values shown on this page.
What is NCT01484093?
NCT01484093 is a phase 1/2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Mantle Cell Lymphoma.
Who leads NCT01484093?
The registry names Andrew Zelenetz, MD,PhD (principal investigator, Memorial Sloan Kettering Cancer Center) as the overall official.
Where does NCT01484093 run?
The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.
When did NCT01484093 end?
The registry lists a primary completion date of 11 Aug 2023 and a study completion date of 11 Aug 2023. The sponsor last updated the record on 16 Aug 2023.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.